hotspot -WSS

hotspot

author：hotspot 2025-08-23 08:56:35 - browse：3

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Color Health wants to make cancer screenings convenient

leisure time

WSS

Humana, CVS hope to turn members into patients at clinics

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

5 ways to address the shortage of health care workers

Childhood vaccination ad campaign launches in the U.K.

5 ways to address the shortage of health care workers

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

hotspot

hotspot

leisure time

The high cost of giving birth even with insurance

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Children’s Hospital revives plan for pedestrian bridge

Peter Hotez and the public health issue of online harassment

The drug industry sees a key ally in the Senate prevail

What does generative AI mean for health care? We asked experts

Neuroscience renaissance leads to new crop of psychiatric drugs

Jerome Adams on the need for new antivirals for Covid

Biden calls for immediate release of Niger's president amid apparent coup

entertainment

Nearly two

NEJM study measures Covid brain fog, impact on IQ

Virtual repurposing can help discover new uses for existing drugs

TytoCare raises $49 million to build out AI

ProMED, early warning system on disease outbreaks, in peril

Elisabeth Bik tackles the widespread issue of research misconduct

knowledge

entertainment

leisure time

entertainment